Key result
Catecholaminergic polymorphic ventricular tachycardia is a rare inherited arrhythmia syndrome managed primarily with beta-blockers, with flecainide and left cardiac sympathetic denervation as additive therapies.
Why the study?
CPVT is an inherited arrhythmia syndrome causing sudden death where early identification, risk stratification, and effective therapy are critical despite ongoing management challenges.
This review provides a comprehensive update on the diagnosis, risk stratification, and stepwise management of CPVT, emphasizing beta-blockers as first-line therapy and highlighting the additive roles of flecainide and left cardiac sympathetic denervation while cautioning against the liberal use of ICDs.
Reinforces beta-blocker primacy with flecainide/LCSD add-ons in CPVT; leaves open refined ICD indications and risk stratification.
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmia syndrome characterised by adenergically mediated bidirectional and/or polymorphic ventricular tachycardia. CPVT is a significant cause of autopsy-negative sudden death in children and adolescents, although it can also affect adults. It is often caused by pathogenic variants in the cardiac ryanodine receptor gene as well as other rarer genes. Early identification and risk stratification is of major importance. β-blockers are the cornerstone of therapy. Sodium channel blockers, specifically flecainide, have an additive role. Left cardiac sympathetic denervation is playing an increasing role in suppression of arrhythmia and symptoms. Concerns have been raised, however, about the efficacy of implantable cardioverter defibrillator therapy and the risk of catecholamine driven proarrhythmic storms. In this review, we summarise the clinical characteristics, genetics, and diagnostic and therapeutic strategies for CPVT and describe recent advances and challenges.
No takes yet. Share an insight, caveat, or question.
Abbas et al. (2022) conducted a review in Catecholaminergic Polymorphic Ventricular Tachycardia. Catecholaminergic polymorphic ventricular tachycardia is a rare inherited arrhythmia syndrome managed primarily with beta-blockers, with flecainide and left cardiac sympathetic denervation as additive therapies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: